Having recently obtained cGMP from Singapore’s Health Sciences Authority, the founders of PrIME Biologics showcase the role of PrIME Technology in driving plasma self-sufficiency in Asia, while highlighting how this innovative technology is disrupting industry standards of plasma fractionation.
Could you please introduce to our international readers the background underlying PrIME Biologic’s foundation?
"The technology itself was introduced to me in 1990 and I was highly impressed by the potentially disruptive nature of this technology, as well as the widespread social impact that it could have in the future."
